![](https://www.pymnts.com/wp-content/uploads/2023/05/Shutterstock_1548396338-2.jpg)
The Federal Trade Commission has filed a lawsuit to prevent Amgen’s acquisition of Horizon Therapeutics, citing concerns about potential competition limitations in the pharmaceutical industry.
According to the FTC, the agreement would strengthen Amgen’s dominance over two of Horizon’s popular drugs: Tepezza for thyroid eye disease, and Krystexxa for gout treatment.
The agency stated that Amgen could provide rebates for their current drugs in an effort to encourage insurers and pharmacy benefit managers to prioritize the two Horizon products through cross-market bundling.
The Federal Trade Commission asserted that Amgen, a company based in California, has a record of using its drug portfolio to obtain benefits over potential competitors.
Related: Amgen, Teva Get Can Appeal Sensipar Antitrust Ruling
The FTC received a suit regarding the acquisition and pending merger between Indivior and Opian, which Senator Elizabeth Warren had previously requested the regulator to scrutinize due to concerns about potential price increases.
“Today’s action – the FTC’s first challenge to a pharmaceutical merger in recent memory – sends a clear signal to the market: The FTC won’t hesitate to challenge mergers that enable pharmaceutical conglomerates to entrench their monopolies at the expense of consumers and fair competition,” said Holly Vedova, agency’s bureau of competition director, in a statement.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI